Cowen Starts Allena Pharmaceuticals (ALNA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- NVIDIA reports 9.3% passive stake in Nebius
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Wedbush Starts Allena Pharmaceuticals (ALNA) at Outperform; Sees $3B Blockbuster Sales Potential from ALLN-177
November 27, 2017 6:32 AM ESTWedbush initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Outperform rating and a price target of $30.00.
Analyst Liana Moussatos sees ALNA as an opportunity to invest in oral enzyme treatments for patients with severe metabolic and kidney disorders.
They project cash... More
Jefferies Starts Allena Pharmaceuticals (ALNA) at Buy
November 27, 2017 2:08 AM ESTJefferies initiates coverage on Allena Pharmaceuticals (NASDAQ: ALNA) with a Buy rating and a price target of $22.00.
Analyst Matt Andrews believes the company's drug, ALLN-177, will be "The Next Big Metabolic Enzyme Blockbuster."
For an analyst ratings summary and ratings history on... More
